Secukinumab efficacy in moderate to severe psoriasis appears not to be affected by previous biologic use: Results of a phase II, regimen-finding trial

被引：0

作者：

Lebwohl, Mark

Elewski, Boni ^{[1
]}

Papavassilis, Charis ^{[2
]}

Thurston, Helen Jane ^{[2
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2013年 / 68卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB212 / AB212

页数：1

共 50 条

[1] Secukinumab efficacy in moderate to severe psoriasis appears not to be affected by previous biologic use: Results of a phase II, dose-ranging trial
Leonardi, Craig
Morita, Akimichi
Richards, Hanno
Thurston, Helen Jane
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB211 - AB211
[2] Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial
Rich, P. A.
Guettner, A.
Sigurgeirsson, B.
Papavassilis, C.
Machacek, M.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB191 - AB191
[3] Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial
Augustin, M.
Abeysinghe, S.
Mallya, U.
Qureshi, A.
Roskell, N.
McBride, D.
Papavassillis, C.
Gelfand, J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (04) : 645 - 649
[4] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Long-term safety and efficacy from an extension of a randomized, phase 2, regimen-finding study
Philipp, S.
Ortonne, J. P.
Thaci, D.
Sigurgeirsson, B.
Kircik, L.
Schopf, R.
Harfst, E.
Thurston, H. J.
Papavassilis, C.
Cooper, S.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 14 - 14
[5] Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
Rich, P.
Sigurgeirsson, B.
Thaci, D.
Ortonne, J. -P.
Paul, C.
Schopf, R. E.
Morita, A.
Roseau, K.
Harfst, E.
Guettner, A.
Machacek, M.
Papavassilis, C.
BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 402 - 411
[6] Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a regimen-finding study
Strober, Bruce
Guettner, Achim
Sigurgeirrson, Bardur
Papavassilis, Charis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
[7] Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
Paul, C.
Reich, K.
Gottlieb, A. B.
Mrowietz, U.
Philipp, S.
Nakayama, J.
Harfst, E.
Guettner, A.
Papavassilis, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (12) : 1670 - 1675
[8] Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)
Blauvelt, Andrew
Gottlieb, Alice
Prinz, Jorg
Pathan, Rashidkhan
Cooper, Simon
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB185 - AB185
[9] Secukinumab efficacy in patients with moderate to severe plaque psoriasis and psoriatic arthritis: A phase II, double-blind, randomized trial
Gottlieb, Alice B.
Guettner, Achim
Papavassilis, Charis
Helliwell, Philip
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
[10] Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
Reich, Kristian
Puig, Lluis
Szepietowski, Jacek C.
Paul, Carle
Lacour, Jean Philippe
Tsianakas, Athanasios
Sieder, Christian
Rissler, Michael
Jagiello, Piotr
Orsenigo, Roberto
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90

← 1 2 3 4 5 →